Effects of the fixed-dose combination therapy with indapamide and valsartan on renal function in patients with Type 2 diabetes mellitus and arterial hypertension
Aim. To study the effects of the fixed-dose combination antihypertensive therapy (noliprel A forte, valsaforce, and indapamide) and the renal function dynamics in patients with Type 2 diabetes mellitus (DM-2) and arterial hypertension (AH). Material and methods. In total, 40 patients with DM-2 and A...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2011-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1962 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850028329527148544 |
|---|---|
| author | T. V. Malykh A. P. Babkin |
| author_facet | T. V. Malykh A. P. Babkin |
| author_sort | T. V. Malykh |
| collection | DOAJ |
| description | Aim. To study the effects of the fixed-dose combination antihypertensive therapy (noliprel A forte, valsaforce, and indapamide) and the renal function dynamics in patients with Type 2 diabetes mellitus (DM-2) and arterial hypertension (AH). Material and methods. In total, 40 patients with DM-2 and AH were randomised into two groups: Group I received noliprel A forte, and Group II received valsaforce and indapamide for two months. The clinical effectiveness of the fixed-dose combination antihypertensive therapy was assessed by 24-hour blood pressure monitoring (BPM), blood biochemistry, and renal function parameters measured at baseline and 8 weeks after the start of the treatment. Results. The treatment was associated with a substantial reduction in BP levels, improved circadian BP profiles, and metabolic neutrality. The therapy with noliprel A forte resulted in markedly improved circadian BP profiles and renal function, as demonstrated by the microalbuminuria dynamics (Rehberg-Tareev test: by 11±0,56 ml/min; Cockgroft-Gault formula: by 12±0,36 ml/min; MDRD formula: by 10±0,16 ml/min/1,73 m2). Conclusion. In patients with DM-2 and AH, the therapy with noliprel A forte significantly improved renal function parameters. |
| format | Article |
| id | doaj-art-5b9cba7a33c34de2ae2183edfa122643 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2011-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-5b9cba7a33c34de2ae2183edfa1226432025-08-20T02:59:52Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252011-12-01106424610.15829/1728-8800-2011-6-42-461674Effects of the fixed-dose combination therapy with indapamide and valsartan on renal function in patients with Type 2 diabetes mellitus and arterial hypertensionT. V. Malykh0A. P. Babkin1N.N. Burdenko Voronezh State Medical AcademyN.N. Burdenko Voronezh State Medical AcademyAim. To study the effects of the fixed-dose combination antihypertensive therapy (noliprel A forte, valsaforce, and indapamide) and the renal function dynamics in patients with Type 2 diabetes mellitus (DM-2) and arterial hypertension (AH). Material and methods. In total, 40 patients with DM-2 and AH were randomised into two groups: Group I received noliprel A forte, and Group II received valsaforce and indapamide for two months. The clinical effectiveness of the fixed-dose combination antihypertensive therapy was assessed by 24-hour blood pressure monitoring (BPM), blood biochemistry, and renal function parameters measured at baseline and 8 weeks after the start of the treatment. Results. The treatment was associated with a substantial reduction in BP levels, improved circadian BP profiles, and metabolic neutrality. The therapy with noliprel A forte resulted in markedly improved circadian BP profiles and renal function, as demonstrated by the microalbuminuria dynamics (Rehberg-Tareev test: by 11±0,56 ml/min; Cockgroft-Gault formula: by 12±0,36 ml/min; MDRD formula: by 10±0,16 ml/min/1,73 m2). Conclusion. In patients with DM-2 and AH, the therapy with noliprel A forte significantly improved renal function parameters.https://cardiovascular.elpub.ru/jour/article/view/1962arterial hypertensiontype 2 diabetes mellitusace inhibitors |
| spellingShingle | T. V. Malykh A. P. Babkin Effects of the fixed-dose combination therapy with indapamide and valsartan on renal function in patients with Type 2 diabetes mellitus and arterial hypertension Кардиоваскулярная терапия и профилактика arterial hypertension type 2 diabetes mellitus ace inhibitors |
| title | Effects of the fixed-dose combination therapy with indapamide and valsartan on renal function in patients with Type 2 diabetes mellitus and arterial hypertension |
| title_full | Effects of the fixed-dose combination therapy with indapamide and valsartan on renal function in patients with Type 2 diabetes mellitus and arterial hypertension |
| title_fullStr | Effects of the fixed-dose combination therapy with indapamide and valsartan on renal function in patients with Type 2 diabetes mellitus and arterial hypertension |
| title_full_unstemmed | Effects of the fixed-dose combination therapy with indapamide and valsartan on renal function in patients with Type 2 diabetes mellitus and arterial hypertension |
| title_short | Effects of the fixed-dose combination therapy with indapamide and valsartan on renal function in patients with Type 2 diabetes mellitus and arterial hypertension |
| title_sort | effects of the fixed dose combination therapy with indapamide and valsartan on renal function in patients with type 2 diabetes mellitus and arterial hypertension |
| topic | arterial hypertension type 2 diabetes mellitus ace inhibitors |
| url | https://cardiovascular.elpub.ru/jour/article/view/1962 |
| work_keys_str_mv | AT tvmalykh effectsofthefixeddosecombinationtherapywithindapamideandvalsartanonrenalfunctioninpatientswithtype2diabetesmellitusandarterialhypertension AT apbabkin effectsofthefixeddosecombinationtherapywithindapamideandvalsartanonrenalfunctioninpatientswithtype2diabetesmellitusandarterialhypertension |